Surface Oncology to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
August 05, 2020 11:59 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces Change to Location and Format of 2020 Annual Meeting of Stockholders
May 28, 2020 16:10 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting
May 15, 2020 07:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting
May 14, 2020 07:30 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present at the UBS Virtual Global Healthcare Conference
May 13, 2020 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020
May 12, 2020 06:20 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
April 23, 2020 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
March 17, 2020 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Mass Innovation Nights Partners with Jobcase for Social Impact Showcase
February 06, 2020 15:18 ET
|
Mass Innovation Nights
CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Mass Innovation Nights (MIN), Massachusetts’ leading new product showcase, is partnering with Jobcase to hold a social impact themed event...
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
January 27, 2020 16:05 ET
|
Surface Oncology, Inc.
Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring Initial clinical updates for SRF617 and SRF388 expected by the end of 2020 Extends current...